Edgewise Therapeutics Appoints John Moore as General Counsel
October 29, 2020
– New executive brings strong legal experience serving as General Counsel for biopharmaceutical companies as Edgewise advances clinical muscular dystrophy program –
Boulder, Colo., (October 29, 2020) – Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of John Moore to the newly created position of General Counsel. Mr. Moore has many years of experience as General Counsel for small molecule biopharmaceutical companies working in a range of therapeutic areas. This comes at an important time as Edgewise advances EDG-5506, the company’s lead product candidate, in clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD).
“We are thrilled to welcome John, another strong leader, to the Edgewise team,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. “John’s deep experience and expertise providing legal oversight and guidance to biopharmaceutical companies will be indispensable to Edgewise both strategically and tactically as we advance our pipeline, including EDG-5506, our lead clinical candidate for DMD and BMD.”
“I’m excited to join Edgewise at this point in the company’s evolution as we build on the ongoing accomplishments of our innovative research engine to move product candidates into the clinic, including progressing EDG-5506 for the treatment of DMD and BMD,” said Mr. Moore. “I look forward to being a part of the team at Edgewise, working to develop new therapies for the treatment of patients with debilitating musculoskeletal disease.”
Prior to joining Edgewise, Mr. Moore was General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s initial public offering (IPO) efforts and was a key advisor on its acquisition by Merck on the eve of its planned IPO. Previously, Mr. Moore served for 15 years as General Counsel and Secretary at Array BioPharma Inc., and for 5 years on the board of directors of Nivalis Therapeutics. Mr. Moore began his legal career as an attorney in private practice. Mr. Moore holds a B.S. in chemistry from the University of North Carolina, an M.S. in biochemistry from the University of Illinois and a J.D. from the University of North Carolina.
About Muscular Dystrophy
Muscular dystrophies are a group of genetic disorders associated with defects in the critical muscle-associated structural protein dystrophin or the sarcomere complex and are characterized by progressive muscle degeneration and weakness. In individuals with neuromuscular conditions such as Duchenne muscular dystrophy, muscle contractions lead to continued rounds of muscle breakdown that the body struggles to repair. Eventually, as patients age, fibrosis and fatty tissue accumulate in the muscle portending a steep decline in physical function that ends with mortality. There remains an unmet need for treatments that reduce muscle breakdown in patients with neuromuscular conditions. Arresting this amplified muscle response will have a dramatic effect on disease progression.
About Edgewise Therapeutics
Edgewise Therapeutics, founded in 2017 by Alan Russell, Ph.D., Peter Thompson, M.D. (Orbimed Advisors) and Badreddin Edris, Ph.D., (Springworks Inc.), is pioneering the development of first-in-class medicines for the treatment of high morbidity musculoskeletal diseases. Skeletal muscle is the largest organ system in the human body, regulating both force production to enable muscle contraction, locomotion, and postural maintenance and the metabolism of glucose, fatty and amino acids. By modulating these processes in skeletal muscle, we create therapeutic agents that will reduce muscle damage, normalize muscle function, decrease mortality and profoundly benefit our patient’s quality of life. To learn more, go to: www.edgewisetx.com
Investors & Media
Kevin Koch, Ph.D.
President and CEO